MedTrace Logo

The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma

NCT02537925 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2015-09-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether celecoxib is effective in the treatment of nasopharyngeal carcinoma by concurrent chemoradiation with weekly nedaplatin.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Celecoxib

Celecoxib 200mg bid po, to the end of concurrent radiotherapy

DRUG

Nedaplatin

40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy

RADIATION

Concurrent Radiotherapy

The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).

Sponsors & Collaborators

  • Changjie Huang

    lead OTHER

Principal Investigators

  • Changjie Huang · The third Affiliated Hospital of Guangxi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02537925 on ClinicalTrials.gov